Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.
Level 5 - mechanism / opinion, no new human data
In vitro bench study using cultured fibroblasts (non-clinical mechanism)
PubMed 25510262 · doi:10.1111/acel.12300
What was done
Researchers used proteomic profiling to examine alterations in the nuclear proteome and protein degradation pathways of Hutchinson-Gilford progeria syndrome (HGPS) cells. They then treated cultured normal and HGPS fibroblasts with sulforaphane (SFN), a cruciferous plant-derived antioxidant, to evaluate its effects on proteasome activity, autophagy, progerin clearance, and cellular disease phenotype.
What was found
The abstract reports no numerical data or effect sizes. Qualitatively, progerin expression was associated with impaired proteasome activity and autophagy. Treatment with sulforaphane stimulated both proteasome activity and autophagy in normal and HGPS fibroblast cultures, enhanced the clearance of progerin through autophagy, and reversed hallmark cellular phenotypic defects of HGPS.
Why it matters
These findings identify impaired protein degradation pathways in progeria and suggest that activating clearance mechanisms with sulforaphane may represent a therapeutic approach for HGPS.
Limits
The study is restricted to in vitro human fibroblast cultures and provides no in vivo efficacy, pharmacokinetic, or safety data. The abstract contains no quantitative metrics, statistical comparisons, or details on sample replicate numbers.
Cited by
- supports Karima Djabali's research group demonstrated that sulforaphane reverses the cellular phenotype in progeria models.